The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.
The University of Chicago Medicine Comprehensive Cancer Center has been granted a six-year, $5 million grant from NCI.
Single-country clinical trial results: Are they applicable to other populations?
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Physician-in-Chief, Orange County; Vice Physician-in-Chief, City of Hope National Medical Center
Table of Contents
YOU MAY BE INTERESTED IN
The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.
FDA added bemotrizinol to the list of permitted sunscreen active ingredients, marking the first new active ingredient added to the over-the-counter sunscreen monograph since the late 1990s.
One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.
An international phase III study showed that patients with relapsed multiple myeloma treated with teclistamab lived longer and remained in remission significantly longer than patients receiving standard therapies.
Adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer, according to the results of a multicenter clinical trial led by researchers at the Johns Hopkins University School of Medicine, Johns Hopkins Kimmel Cancer Center, Department of Radiation Oncology and Molecular Radiation Sciences, and Brady Urological Institute.
